The Future of Ovarian Cancer Treatment
Oncologists contemplate what ovarian cancer treatment will look like in the future and exciting clinical trials in progress.
Ovarian Cancer Maintenance Therapy Clinical Pearls
Robert W. Holloway, MD, and Chad A. Hamilton, MD, provide clinical pearls for community physicians using maintenance therapies for ovarian cancer.
Ovarian Cancer Maintenance Therapy: Olaparib vs. Niraparib
Key opinion leaders discuss how they decide between two regimens for ovarian cancer maintenance therapies.
Case Scenario: Stage 3C High-Grade Serous Ovarian Cancer
Experts review the potential maintenance therapy approaches for a 64-year-old woman with stage IIIC high-grade serous ovarian cancer.
Ovarian Cancer: Significant Clinical Trials
Dr. Chad Hamilton explains pivotal data from several important clinical trials in ovarian cancer.
Starting Maintenance Therapy for Ovarian Cancer
Robert W. Holloway, MD, details how he decides to start maintenance therapy after first-line ovarian cancer treatments.
Case Scenario: Stage 3A High-Grade Epithelial Ovarian Cancer
Chad A. Hamilton, MD, and Robert W. Holloway, MD, review the case of a 57-year-old woman with stage IIIA high-grade epithelial ovarian cancer.
Genetic Counseling for Ovarian Cancer
Oncologists debate the need for genetic counseling for ovarian cancer patients and how to approach molecular testing alongside neoadjuvant chemotherapy.
Sequencing of Biomarker Testing for Ovarian Cancer
Dr Robert W. Holloway explains his typical approach to ovarian cancer biomarker testing and sequencing.
Molecular Testing and Ovarian Cancer
Chad A. Hamilton, MD, and Robert W. Holloway, MD, discuss challenges clinicians face in treating ovarian cancer and review the current state of biomarker testing.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512